Myocardial ischemia-reperfusion injury remains a significant challenge in the treatment of acute myocardial infarction (MI). Despite timely reperfusion using thrombolytic therapy or primary percutaneous coronary intervention (PPCI), reperfusion can cause further cardiomyocyte death, known as reperfusion injury. This injury is characterized by oxidative stress, calcium overload, mitochondrial permeability transition pore (MPTP) opening, and inflammation, leading to myocardial damage. Current therapeutic strategies for preventing reperfusion injury include mechanical interventions like ischemic postconditioning (IPost) and remote ischemic conditioning (RIC), as well as pharmacologic agents such as cyclosporin A and exenatide. These strategies aim to reduce MI size and improve clinical outcomes. However, effective therapies for reperfusion injury remain limited, and further research is needed to translate promising laboratory findings into clinical practice. Cardiac MRI is a valuable tool for assessing acute myocardial reperfusion injury and evaluating the efficacy of therapeutic strategies. Despite advances in reperfusion techniques and cardioprotective agents, myocardial reperfusion injury remains a critical target for improving outcomes in patients with acute MI. Ongoing clinical trials are investigating the potential of these emerging strategies to reduce reperfusion injury and improve survival in patients with STEMI.Myocardial ischemia-reperfusion injury remains a significant challenge in the treatment of acute myocardial infarction (MI). Despite timely reperfusion using thrombolytic therapy or primary percutaneous coronary intervention (PPCI), reperfusion can cause further cardiomyocyte death, known as reperfusion injury. This injury is characterized by oxidative stress, calcium overload, mitochondrial permeability transition pore (MPTP) opening, and inflammation, leading to myocardial damage. Current therapeutic strategies for preventing reperfusion injury include mechanical interventions like ischemic postconditioning (IPost) and remote ischemic conditioning (RIC), as well as pharmacologic agents such as cyclosporin A and exenatide. These strategies aim to reduce MI size and improve clinical outcomes. However, effective therapies for reperfusion injury remain limited, and further research is needed to translate promising laboratory findings into clinical practice. Cardiac MRI is a valuable tool for assessing acute myocardial reperfusion injury and evaluating the efficacy of therapeutic strategies. Despite advances in reperfusion techniques and cardioprotective agents, myocardial reperfusion injury remains a critical target for improving outcomes in patients with acute MI. Ongoing clinical trials are investigating the potential of these emerging strategies to reduce reperfusion injury and improve survival in patients with STEMI.